Kwalitity Pharmaceuticals Limited has submitted its mandatory compliance certificate under SEBI regulations for the quarter ended March 31, 2026. The pharmaceutical company filed the certificate with BSE Limited on April 08, 2026, fulfilling its regulatory obligations under the Securities and Exchange Board of India framework.

Regulatory Compliance Certificate

The certificate was issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This regulation mandates that companies confirm the proper handling of securities received for dematerialization during each quarter.

Certificate Details

Bigshare Services Private Limited, serving as the company's Registrar and Share Transfer Agent, issued the confirmation certificate on April 06, 2026. The certificate confirms that all securities received from depository participants for dematerialization up to March 31, 2026 were properly confirmed to the depositories.

The registrar verified that:

• Securities received for dematerialization were accepted or rejected as appropriate
• All securities are listed on stock exchanges where previously issued securities are traded
• Security certificates were mutilated and cancelled after proper verification
• Depository names were substituted in the register of members within the required 15-day timeframe

Corporate Compliance

Gurpreet Kaur, Company Secretary and Compliance Officer, submitted the certificate to BSE Limited's Department of Corporate Services. The submission ensures the company maintains its compliance status with SEBI's depositories and participants regulations.

This quarterly filing represents part of the company's ongoing regulatory compliance obligations, ensuring transparency in share dematerialization processes and maintaining good standing with market regulators and stock exchanges.

KwalitY Pharmaceuticals Limited has successfully concluded its postal ballot voting process, with shareholders overwhelmingly approving two special resolutions for the appointment of independent directors. The company announced the results on March 30, 2026, demonstrating strong shareholder confidence in the proposed board appointments.

Voting Results Overview

The postal ballot process yielded exceptional approval rates for both resolutions, with shareholders showing near-unanimous support for the company's governance initiatives.

Resolution Details and Approval

Both special resolutions received identical voting patterns, reflecting consistent shareholder sentiment across the proposed appointments.

Resolution 1: Appointment of Mr. Preetmohinder Singh Bedi

The first resolution concerned the appointment of Mr. Preetmohinder Singh Bedi (DIN: 11452004) as an Independent Director for a term of 5 consecutive years.

Resolution 2: Appointment of Mr. Bhavesh Mahajan

The second resolution approved the appointment of Mr. Bhavesh Mahajan (DIN: 09614108) as an Independent Director for a period of 5 consecutive years.

Voting Process and Timeline

The company conducted the postal ballot process through remote e-voting, ensuring accessibility for all shareholders while maintaining transparency and compliance.

Scrutinizer Appointment and Report

Rishi Mittal & Associates, Company Secretaries, served as the appointed scrutinizer for the postal ballot process. Rishi Mittal (ACS No. 12613) was appointed by the Board of Directors on February 21, 2026, and submitted the scrutinizer's report on March 29, 2026. The scrutinizer confirmed that both special resolutions were passed with the requisite majority, as the votes cast in favour exceeded three times the number of votes cast against them.

The company utilized National Securities Depository Limited (NSDL) services for the remote e-voting facility, ensuring a secure and transparent voting process for all eligible shareholders. Company Secretary Gurpreet Kaur (ACS No: 52091) served as the Compliance Officer for the process and communicated the results to the Bombay Stock Exchange under scrip code 539997.